Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000081893 | SCV000228162 | pathogenic | not provided | 2012-11-14 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000081893 | SCV000582388 | pathogenic | not provided | 2023-03-24 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Has not been previously published as pathogenic or benign to our knowledge |
Invitae | RCV000810563 | SCV000950776 | pathogenic | Cohen syndrome | 2023-10-06 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg1200*) in the VPS13B gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in VPS13B are known to be pathogenic (PMID: 15141358, 16648375, 20461111). This variant is present in population databases (rs140353201, gnomAD 0.008%). This variant has not been reported in the literature in individuals affected with VPS13B-related conditions. ClinVar contains an entry for this variant (Variation ID: 95846). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Ce |
RCV000081893 | SCV001500518 | pathogenic | not provided | 2021-02-01 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000810563 | SCV003816620 | likely pathogenic | Cohen syndrome | 2022-06-03 | criteria provided, single submitter | clinical testing | |
New York Genome Center | RCV000810563 | SCV003925424 | pathogenic | Cohen syndrome | 2022-02-09 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003894940 | SCV004716024 | likely pathogenic | VPS13B-related disorder | 2024-03-01 | criteria provided, single submitter | clinical testing | The VPS13B c.3598C>T variant is predicted to result in premature protein termination (p.Arg1200*). To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0080% of alleles in individuals of African descent in gnomAD. Nonsense variants in VPS13B are expected to be pathogenic. This variant is interpreted as likely pathogenic. |
Natera, |
RCV000810563 | SCV001454827 | pathogenic | Cohen syndrome | 2020-09-16 | no assertion criteria provided | clinical testing |